idea-005 · human · US
For unattended recording of respiratory airflow, respiratory effort, oxygen saturation, pulse rate, and body position in the home, in children aged 5 through 17 years with clinical suspicion of obstructive sleep apnea and without neuromuscular disease, craniofacial syndrome, Down syndrome, sickle cell disease, obesity hypoventilation, or significant cardiopulmonary disease, for interpretation by a qualified sleep physician.
Finished enough to read, and waiting for you. No department has been asked. 11 of 43 claims verified, 1 refuted. Nobody has yet written down what it rests on.
A sleep-apnea test a child can do at home instead of spending a night wired up in a hospital sleep lab. Children with obstructive sleep apnea — usually caused by enlarged tonsils and adenoids — are diagnosed today by an overnight in-laboratory study, which is scarce, expensive, and often months away. This is a portable recorder a parent fits at bedtime: sensors for airflow at the nose, bands around the chest and abdomen to measure breathing effort, and a finger probe for blood oxygen, with scoring software tuned to children's thresholds rather than adults'. It deliberately leaves out the brainwave sensors a lab study uses, which is what makes it simple enough to use at home — and, as this packet shows, is also the core of the objection to it.
In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: pediatric-obstructive-sleep-apnea-testing
check_cpt_code cannot return
verified/refuted under any circumstance, and no HCPCS (Healthcare Common Procedure Coding System) alternative has been established
either (hcpcs/payment/coverage all returned missing-cache unconfirmed on this build,
matching the candidate's own record).
The chain's weakest link is the payer, not the buyer. The practice-level transaction claim 6unconfirmed is a normal diagnostic-services purchase; what makes the chain fragile is that the file's own load-bearing reimbursement claim is an assertion of absence of coverage for exactly the population this candidate targets.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-005 replaces this list with the real one.
Why it scored what it did: Scoreable: intended_use: is present, specific, and names the excluded comorbidity populations, so there is a real indication to classify against. Rests on the device_class block (both routes) and on claim 3refuted (no HSAT (home sleep apnoea test) device carries a…the rest of this reasoning
pediatric OSA (obstructive sleep apnoea) indication). Scored as an unresolved 510(k) (premarket notification)-vs-De Novo (De Novo classification request) fork, not as the cheaper branch. The Generator itself rates De Novo at least as likely, no product code or regulation number has been identified for either route, and the named analogs (ApneaLink Air, WatchPAT, Alice NightOne) come from web search with no clearance letter read. The structural problem is that claim 3refuted is load-bearing in both directions at once: the absence of any pediatric-indicated HSAT is what makes the whitespace attractive and is the fact that most threatens substantial equivalence on intended population. A 3 would require evidence the 510(k) branch is live; nothing in the file supplies it
What would settle it: openFDA classification lookup for the product code and regulation number, a clearance lookup reading Indications-for-Use text for ApneaLink, WatchPAT, and Alice NightOne, the FDA De Novo listing for a granted pediatric sleep-test De Novo,…the rest of this gap analysis
and eCFR text for the regulation — all free. The predicate-acceptance question itself needs an FDA Pre-Submission meeting (filing fee plus review calendar)
Why it scored what it did: Rests on claim 8unconfirmed (commercial and Medicaid policies generally exclude HSAT under 18), claim 9unconfirmed (the conditional: if that exclusion is written as an age restriction rather than a clearance restriction, FDA clearance alone does not unlock…the rest of this reasoning
payment), and claims 1-2 (the CPT codes). Scored 1 rather than 2 because this is the rare file where the load-bearing reimbursement claim is an assertion of absence — the pathway story here is "clear the device, then run a second, serial policy-change campaign", which is not a pathway, it is a second company. Compounding it: claims 1 and 2 are CPT descriptor claims, and connectors/reimbursement.py::check_cpt_code cannot return verified/refuted for AMA-licensed descriptors under any circumstance, so the code layer beneath this factor can only ever be closed by a human. claim 2unconfirmed is flagged by the Generator itself as a guessed descriptor. Note this 1, paired with Regulatory at 2, does not trip the Stage 5 both-below-2 kill (2 is at the floor, not below it) — but there is no margin
What would settle it: A coverage lookup against CMS (Centers for Medicare & Medicaid Services) NCD 240.4 (a Medicare national coverage determination number) and the relevant MAC (Medicare administrative contractor) LCD (local coverage determination)/LCA (free), 2-3 named commercial and state-Medicaid sleep-testing policies read by hand (staff time, no fee), and a payment-rate lookup for the allowed amount (free). The CPT…the rest of this gap analysis
descriptors need a licensed AMA CPT 2026 source (licensing fee) that no connector can ever provide
Why it scored what it did: Decomposes into claim 5unconfirmed (C1, pediatric PSG annual volume — no number stated), claim 6unconfirmed (C2, $150-300 net price — Generator assumption anchored to unverified adult pricing), claim 7unconfirmed (C3, 30-50% addressable share — assumption resting on a…the rest of this reasoning
further unverified belief that in-lab pediatric bed capacity is the rate limiter). Same structure as every thin TAM: the revenue-determining components (C2 x C3) are the two with no source, so even a fully successful Verifier pass leaves this partially evidenced. Specific to this candidate: the standard procedures route reads CMS Part B / Medicare utilization, and the target population is children aged 5-17, who are essentially absent from Medicare FFS (fee-for-service). So a null or near-null volume result here would be an artifact of the wrong denominator, not evidence of a small market, and must not be scored as one. Held at 2 rather than 1 because the underlying clinical population (pediatric OSA in school-age children) is uncontroversially large and the referral pathway is well established; held at 2 rather than 3 because not one dollar of the TAM currently rests on a source
What would settle it: A Medicare procedure-volume lookup as a wrong-denominator floor (free); HCUP KID/NIS, a commercial claims database (MarketScan/Komodo), and Medicaid T-MSIS/TAF for real pediatric volume and payer mix (licensed data, subscription cost).…the rest of this gap analysis
Price needs a payment-rate lookup plus a licensed adult-HSAT price benchmark; share needs a human-attached count of AASM-accredited pediatric beds and wait times (no fee, not connector-reachable)
Why it scored what it did: No claim in the Claims section addresses freedom to operate, blocking patents, or expiry timelines at all — not even a hole-acknowledging one. Left blank rather than scored: a number here would be invented, and at 15% weight an…the rest of this reasoning
invented number is the most damaging thing this table could contain. Read this as unexamined, in neither direction — it is not an FTO (freedom to operate)-clear signal, and it is not a kill signal either, since the Stage 5 FTO kill fires only on an identified live enforceable patent found on evidence. Given three well-capitalized incumbents (claim 13unconfirmed) sitting on decades of HSAT hardware and signal-processing portfolios, unexamined is a materially risky place for the highest-weighted unscored factor to be. This is the largest single gap in the file and should be closed by the Generator adding an FTO claim before or alongside Stage 3
What would settle it: A USPTO (United States Patent and Trademark Office) Patent Public Search / Google Patents sweep over the relevant CPC classes and named incumbent assignees (free), followed by a per-patent status/expiry lookup once candidate numbers surface. Full settlement is a counsel-drafted FTO…the rest of this gap analysis
memo at Stage 7 (legal fees)
Why it scored what it did: Rests entirely on claim 10unconfirmed: the pediatric concurrent-PSG validation dataset, the scoring algorithm derived from it, and the cleared pediatric indication itself. The first half is a genuine barrier — several hundred children with concurrent…the rest of this reasoning
in-lab PSG is slow and expensive (claim 12unconfirmed), and it is the kind of asset that cannot be bought quickly. The second half — that payers will condition coverage on clearance for that age range — is explicitly an assumption about how policy language gets drafted, and it is the half that would make the moat durable rather than merely costly. Scored 2 because the moat is structurally two-edged with Factor 8: claim 13unconfirmed says incumbents are one validation study from parity, so the moat holds only for as long as the segment is too small to interest them — which is the same sentence as "the TAM may be too small." No patent-based moat is claimed, consistent with Factor 4 resting on nothing
What would settle it: The FTO patent search above, read offensively for algorithm patentability (free); a trial-detail lookup on the two registered NCTs for who is running the pediatric validation dataset (free, near-decisive); a clearance-history pull over the…the rest of this gap analysis
trailing 5 years for the fast-follower rate (free); and a human-attached named payer policy that conditions coverage on age-specific clearance (no connector reaches policy language)
Why it scored what it did: Rests on claim 11unconfirmed (dominant risk is false negatives: pediatric OSA presents at lower AHI with more partial obstruction and arousal-based events, and a cannula-and-belt montage without EEG cannot see arousals or normalise by true sleep…the rest of this reasoning
time) and on the indication-scope note, which honestly concedes the device cannot see central events or hypoventilation without CO2 and carves those populations out. Safety risk is minimal — non-invasive, non-implanted, home recorder. Scored 2 nonetheless because the named dominant risk is unmitigated and unmeasured: the comorbidity exclusions address the central/hypoventilation failure mode but do nothing about the false-negative mode, and "can a no-EEG montage hit acceptable sensitivity against pediatric PSG" is simultaneously the core technical bet, the determinant of the validation study's size (and therefore of Factor 7), and completely unevidenced in this file. claim 4unconfirmed is bibliographic existence only — two NCT numbers with no result, no sample size, no comparator — and says nothing about performance in either direction
What would settle it: Trial-detail lookups on the two registered NCTs for design, sample size, and posted results (free, the highest information-per-call check in the file); a literature search on pediatric HSAT-vs-PSG concordance (free); and a human read of…the rest of this gap analysis
the licensed AASM pediatric scoring manual (licensing cost)
Why it scored what it did: Rests on claim 12unconfirmed (prospective multi-site validation with concurrent in-lab PSG in several hundred children; mid-single-digit millions; 2-4 years to first revenue), which the Generator states is benchmarked against no actual pediatric…the rest of this reasoning
device study. Scored 1 because three independent structures in this file push the estimate up and none pulls it down: (i) the De Novo branch of the regulatory fork adds review time and evidence burden over the 510(k) assumption the estimate appears to price; (ii) claim 11unconfirmed's false-negative problem drives the study larger, since demonstrating sensitivity for low-AHI arousal-based events needs more children than demonstrating agreement on obvious cases; (iii) claim 9unconfirmed means first revenue may not begin at clearance at all but after a serial payer-policy campaign that carries its own cost and calendar and is currently costed at zero. Pediatric enrollment requiring an overnight in-lab reference study is also slow to recruit. This is a hero-bet capital profile attached to a niche indication
What would settle it: Trial-detail lookups on the two NCTs for realized enrollment, sites, and timelines (free, the best available benchmark); FDA MDUFA performance reports and the FDA De Novo decision-time listing (free); and a human-attached CRO quote for a…the rest of this gap analysis
multi-site pediatric study (the quote itself is typically free)
Why it scored what it did: Rests on claim 13unconfirmed (ResMed, ZOLL/Itamar and Philips hold cleared adult HSAT platforms one validation study away from this indication; the real question is whether the segment is large enough for them to bother). Scored 2 on the convention…the rest of this reasoning
that higher intensity is worse: the incumbents are well-capitalized, already cleared, already in the referral channel, and face a strictly lower barrier to this indication than a new entrant does, since they need only add a population to an existing platform. The apparent counterweight — that per claim 3refuted none of them has bothered — cuts both ways and neither way is good: either the segment is unattractive (a TAM problem) or the pediatric validation study is harder than claim 12unconfirmed prices it (a Factor 7 problem). The second half of claim 13unconfirmed is a guess about incumbent internal priorities with no source and no connector
What would settle it: A clearance-history pull over the trailing 5 years (free) settles the incumbent roster and cleared indications; a recall-history pull (free) adds safety-signal context; and a trial-detail lookup on the two NCTs' sponsor fields (free,…the rest of this gap analysis
near-decisive). Funding and launch activity needs a licensed source like PitchBook or Crunchbase (subscription cost)
Why it scored what it did: No claim in this file speaks to strategic fit, and the repo contains no portfolio thesis, no stated capital constraints and no hero-bet-versus-cash-spoke allocation policy; calibration-log.md is still empty, so there is no track record…the rest of this reasoning
to position against either. The 3 is a placeholder, not an assessment. What the file's own evidence does support as a characterization: this is a hero-bet profile — multi-year validation study, mid-single-digit-millions before revenue (claim 12unconfirmed), an unresolved regulatory fork, and a serial payer campaign after clearance (claim 9unconfirmed) — attached to a niche pediatric indication. That is a real description and still says nothing about whether it fits this portfolio, because no portfolio has been defined. At 5% weight this moves any future composite by at most 1 point either way. Read it as a null; it does not carry into Stage 4
What would settle it: A human-authored portfolio thesis document covering current holdings, capital constraints, and hero-bet-vs-cash-spoke targets — no external source exists; the cost is internal strategy time, not a data fee
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-005 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
1 claim(s) the Verifier found to be false — a refuted claim is a finding, and the loop owes each one an answer.
Read three named commercial medical policies and two state Medicaid policies for home sleep testing, specifically for how the under-18 exclusion is worded — as an age restriction or as a device-clearance restriction. The Scores table isolates this distinction as the conditional the whole reimbursement factor turns on, and the file records no primary source behind the exclusion claim at all. Five documents, read by hand, before any part of the mid-single-digit-million validation study is commissioned. Selected from the Reimbursement row's gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
Evaluated 2026-08-23 against the Verified Composite above, using verified claims only. The Stage 2 draft table was not consulted. Unchecked boxes mean the condition did not fire. This file is the only one in its batch carrying a refuted claim, so read the first note carefully — a refutation is active negative evidence, but only for the factors it actually speaks to.
unverifiable by design (AMA-licensed) and the coverage question hit the missing cache.
unconfirmed — one a missing-cache-plus-wrong-denominator (children are
essentially absent from Medicare FFS, so a null there is an artifact, not a small market),
two market-unverifiable. **Scoring TAM to 1 would have manufactured a kill out of evidence
that quantifies nothing.** The operand stays undefined and the floor was not applied.
claim 3refuted — "no HSAT device carries a pediatric indication" — is refuted, and it was the candidate's entire whitespace premise. It moved three factors in two directions: Regulatory up to 4 (a pediatric-indicated predicate demonstrably exists), Moat down to 1 (the "cleared pediatric indication is itself the moat" asset is verifiably not exclusive), and Competitive intensity down to 1 (the incumbents are not "one validation study away" — one has already arrived). Those were scored separately and never averaged.
A refuted premise is not automatically a kill. None of the three kill conditions is written over Moat or Competitive intensity, which are the factors the refutation actually damaged. The rubric's conditions read Regulatory, Reimbursement, TAM and FTO — and on this one the refutation helped the only one of those with any evidence behind it. That is an uncomfortable result and it is the correct one: the idea is materially weaker than when it was generated, and no hard gate has grounds to fire.
cpt, which is unverifiable by design because CPT is
AMA-licensed, and needs a human-attached licensed source. The load-bearing coverage question
— whether payer exclusions are worded as an age restriction or a device-clearance
restriction — is unresolved, and that single distinction decides whether FDA clearance alone
would unlock payment.
status: set to queued-research; stage: stays verified — the
Verifier attempted every claim, so the pass is complete and must not be regressed.
wrapped is not an approval — it means a human can now read this.
No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-005 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-005 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A sleep-apnea test a child can do at home instead of spending a night wired up in a hospital sleep lab. Children with obstructive sleep apnea — usually caused by enlarged tonsils and adenoids — are diagnosed today by an overnight in-laboratory study, which is scarce, expensive, and often months away. This is a portable recorder a parent fits at bedtime: sensors for airflow at the nose, bands around the chest and abdomen to measure breathing effort, and a finger probe for blood oxygen, with scoring software tuned to children's thresholds rather than adults'. It deliberately leaves out the brainwave sensors a lab study uses, which is what makes it simple enough to use at home — and, as this packet shows, is also the core of the objection to it.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Read three named commercial medical policies and two state Medicaid policies for home sleep testing, specifically for how the under-18 exclusion is worded — as an age restriction or as a device-clearance restriction. The Scores table isolates this distinction as the conditional the whole reimbursement factor turns on, and the file records no primary source behind the exclusion claim at all. Five documents, read by hand, before any part of the mid-single-digit-million validation study is commissioned. Selected from the Reimbursement row's gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 7 of 33 claims verified, 25 unconfirmed, 1 refuted. All 9 factors carry a score in the Stage 2 triage table and all 4 core factors do.
This is the best-evidenced candidate in the portfolio on whether the device could work, and among the least evidenced on whether anyone would pay for it. All seven verified claims are clinical or regulatory; not one is commercial. The payer question its own conditional says decides the business has no primary source behind it at all.
The verified evidence is genuinely mixed and a Stage 6 reader should have both halves.
Against. The AASM's 2017 Position Paper states that home sleep apnea testing is not recommended for diagnosing obstructive sleep apnea in children — and the stated reason is the inability to identify literature on devices that monitor CO2 or detect arousals, which the task force viewed as critical in this population claim 28verified. Arousal detection is what the brainwave channel provides, and omitting it is this product's defining design choice. The 2012 AAP technical report separately found that most diagnostic screening tests in this condition had low sensitivity and specificity claim 29verified.
In favour. A 2026 systematic review found that in one of the largest simultaneous HSAT-versus-PSG comparisons, mean AHI was 2.5±3 by home test versus 2.7±2.9 in lab, p>0.05 claim 30verified — close agreement, on an EEG-free modality, at the AHI values where the treatment decision is actually made. Home testing is also demonstrably practical for families: in an Australian cohort of 47 children aged 5-16, acceptable recordings were obtained for every home study attempted, with a 6.6% false-positive and 3% false-negative rate claim 31verified. And the burden of the current pathway is real: a Québec series of 82 consecutive adenotonsillectomy patients recorded a mean referral-to-surgery delay of 15.2±8.6 months claim 32verified.
Three cautions on reading those. The favourable feasibility result claim 31verified used home Type-2 polysomnography, a montage that includes EEG — so it does not evidence the EEG-free design this candidate proposes. The same systematic review that supplies the favourable concordance figure also reports that only 3 of 9 included studies used simultaneous testing claim 30verified, so that evidence base is three studies deep. And both claim 31verified and claim 32verified are non-US studies carrying jurisdiction: US, describing health systems whose access patterns are not the US market's.
Finally, the file's founding premise was refuted, and this remains the most structurally important fact in it: a cleared home airflow/effort recorder already states verbatim that "both pediatric and adult patients may be tested", from a roster of 38 MNR clearances over 2020-2026 claim 3refuted. The pediatric-permitting pathway is demonstrably walkable, several parties have walked it, and the practice has not moved. That refutation cost the candidate its white-space argument and simultaneously supplied its regulatory identification claim 26verified — a refuted claim that is also the most informative one in the file. What the seven verified claims add is a candidate explanation for the silence: not that clearance was unavailable, but that the professional society does not recommend the modality, for a reason aimed at this device's architecture. FTO is unexamined rather than clear claim 25unconfirmed, in a field with 38 clearances, on the rubric's one automatic-kill factor.
One defect in the file worth naming rather than quietly working around: claim 33unconfirmed points at "claim 38unverified" as its revealed-behaviour twin, but this file has 33 claims and the study it describes is claim 32verified. Claims are append-only and positional, so the reference is stale rather than ambiguous. It has been left as recorded — rewriting a claim's text would be editing evidence — and the decks cite claim 32verified directly.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 2 | Scoreable: intended_use: is present, specific, and names the excluded comorbidity populations, so there is a real indication to classify against. Rests on the device_class block (both routes) and on claim 3refuted (no HSAT device carries a…the rest of this reasoningpediatric OSA indication). Scored as an unresolved 510(k)-vs-De Novo fork, not as the cheaper branch. The Generator itself rates De Novo at least as likely, no product code or regulation number has been identified for either route, and the named analogs (ApneaLink Air, WatchPAT, Alice NightOne) come from web search with no clearance letter read. The structural problem is that claim 3refuted is load-bearing in both directions at once: the absence of any pediatric-indicated HSAT is what makes the whitespace attractive and is the fact that most threatens substantial equivalence on intended population. A 3 would require evidence the 510(k) branch is live; nothing in the file supplies it | openFDA classification lookup for the product code and regulation number, a clearance lookup reading Indications-for-Use text for ApneaLink, WatchPAT, and Alice NightOne, the FDA De Novo listing for a granted pediatric sleep-test De Novo,…the rest of this gap analysisand eCFR text for the regulation — all free. The predicate-acceptance question itself needs an FDA Pre-Submission meeting (filing fee plus review calendar) |
| Reimbursement pathway | 1 | Rests on claim 8unconfirmed (commercial and Medicaid policies generally exclude HSAT under 18), claim 9unconfirmed (the conditional: if that exclusion is written as an age restriction rather than a clearance restriction, FDA clearance alone does not unlock…the rest of this reasoningpayment), and claims 1-2 (the CPT codes). Scored 1 rather than 2 because this is the rare file where the load-bearing reimbursement claim is an assertion of absence — the pathway story here is "clear the device, then run a second, serial policy-change campaign", which is not a pathway, it is a second company. Compounding it: claims 1 and 2 are CPT descriptor claims, andconnectors/reimbursement.py::check_cpt_code cannot return verified/refuted for AMA-licensed descriptors under any circumstance, so the code layer beneath this factor can only ever be closed by a human. claim 2unconfirmed is flagged by the Generator itself as a guessed descriptor. Note this 1, paired with Regulatory at 2, does not trip the Stage 5 both-below-2 kill (2 is at the floor, not below it) — but there is no margin | A coverage lookup against CMS NCD 240.4 and the relevant MAC LCD/LCA (free), 2-3 named commercial and state-Medicaid sleep-testing policies read by hand (staff time, no fee), and a payment-rate lookup for the allowed amount (free). The CPT…the rest of this gap analysisdescriptors need a licensed AMA CPT 2026 source (licensing fee) that no connector can ever provide |
| TAM | 2 | Decomposes into claim 5unconfirmed (C1, pediatric PSG annual volume — no number stated), claim 6unconfirmed (C2, $150-300 net price — Generator assumption anchored to unverified adult pricing), claim 7unconfirmed (C3, 30-50% addressable share — assumption resting on a…the rest of this reasoningfurther unverified belief that in-lab pediatric bed capacity is the rate limiter). Same structure as every thin TAM: the revenue-determining components (C2 x C3) are the two with no source, so even a fully successful Verifier pass leaves this partially evidenced. Specific to this candidate: the standardprocedures route reads CMS Part B / Medicare utilization, and the target population is children aged 5-17, who are essentially absent from Medicare FFS. So a null or near-null volume result here would be an artifact of the wrong denominator, not evidence of a small market, and must not be scored as one. Held at 2 rather than 1 because the underlying clinical population (pediatric OSA in school-age children) is uncontroversially large and the referral pathway is well established; held at 2 rather than 3 because not one dollar of the TAM currently rests on a source | A Medicare procedure-volume lookup as a wrong-denominator floor (free); HCUP KID/NIS, a commercial claims database (MarketScan/Komodo), and Medicaid T-MSIS/TAF for real pediatric volume and payer mix (licensed data, subscription cost).…the rest of this gap analysisPrice needs a payment-rate lookup plus a licensed adult-HSAT price benchmark; share needs a human-attached count of AASM-accredited pediatric beds and wait times (no fee, not connector-reachable) |
| FTO / IP | *(blank — no claim exists)* | No claim in the Claims section addresses freedom to operate, blocking patents, or expiry timelines at all — not even a hole-acknowledging one. Left blank rather than scored: a number here would be invented, and at 15% weight an…the rest of this reasoninginvented number is the most damaging thing this table could contain. Read this as unexamined, in neither direction — it is not an FTO-clear signal, and it is not a kill signal either, since the Stage 5 FTO kill fires only on an identified live enforceable patent found on evidence. Given three well-capitalized incumbents (claim 13unconfirmed) sitting on decades of HSAT hardware and signal-processing portfolios, unexamined is a materially risky place for the highest-weighted unscored factor to be. This is the largest single gap in the file and should be closed by the Generator adding an FTO claim before or alongside Stage 3 | A USPTO Patent Public Search / Google Patents sweep over the relevant CPC classes and named incumbent assignees (free), followed by a per-patent status/expiry lookup once candidate numbers surface. Full settlement is a counsel-drafted FTO…the rest of this gap analysismemo at Stage 7 (legal fees) |
| Moat / defensibility | 2 | Rests entirely on claim 10unconfirmed: the pediatric concurrent-PSG validation dataset, the scoring algorithm derived from it, and the cleared pediatric indication itself. The first half is a genuine barrier — several hundred children with concurrent…the rest of this reasoningin-lab PSG is slow and expensive (claim 12unconfirmed), and it is the kind of asset that cannot be bought quickly. The second half — that payers will condition coverage on clearance for that age range — is explicitly an assumption about how policy language gets drafted, and it is the half that would make the moat durable rather than merely costly. Scored 2 because the moat is structurally two-edged with Factor 8: claim 13unconfirmed says incumbents are one validation study from parity, so the moat holds only for as long as the segment is too small to interest them — which is the same sentence as "the TAM may be too small." No patent-based moat is claimed, consistent with Factor 4 resting on nothing | The FTO patent search above, read offensively for algorithm patentability (free); a trial-detail lookup on the two registered NCTs for who is running the pediatric validation dataset (free, near-decisive); a clearance-history pull over the…the rest of this gap analysistrailing 5 years for the fast-follower rate (free); and a human-attached named payer policy that conditions coverage on age-specific clearance (no connector reaches policy language) |
| Mechanism & clinical risk | 2 | Rests on claim 11unconfirmed (dominant risk is false negatives: pediatric OSA presents at lower AHI with more partial obstruction and arousal-based events, and a cannula-and-belt montage without EEG cannot see arousals or normalise by true sleep…the rest of this reasoningtime) and on the indication-scope note, which honestly concedes the device cannot see central events or hypoventilation without CO2 and carves those populations out. Safety risk is minimal — non-invasive, non-implanted, home recorder. Scored 2 nonetheless because the named dominant risk is unmitigated and unmeasured: the comorbidity exclusions address the central/hypoventilation failure mode but do nothing about the false-negative mode, and "can a no-EEG montage hit acceptable sensitivity against pediatric PSG" is simultaneously the core technical bet, the determinant of the validation study's size (and therefore of Factor 7), and completely unevidenced in this file. claim 4unconfirmed is bibliographic existence only — two NCT numbers with no result, no sample size, no comparator — and says nothing about performance in either direction | Trial-detail lookups on the two registered NCTs for design, sample size, and posted results (free, the highest information-per-call check in the file); a literature search on pediatric HSAT-vs-PSG concordance (free); and a human read of…the rest of this gap analysisthe licensed AASM pediatric scoring manual (licensing cost) |
| Capital intensity & time-to-revenue | 1 | Rests on claim 12unconfirmed (prospective multi-site validation with concurrent in-lab PSG in several hundred children; mid-single-digit millions; 2-4 years to first revenue), which the Generator states is benchmarked against no actual pediatric…the rest of this reasoningdevice study. Scored 1 because three independent structures in this file push the estimate up and none pulls it down: (i) the De Novo branch of the regulatory fork adds review time and evidence burden over the 510(k) assumption the estimate appears to price; (ii) claim 11unconfirmed's false-negative problem drives the study larger, since demonstrating sensitivity for low-AHI arousal-based events needs more children than demonstrating agreement on obvious cases; (iii) claim 9unconfirmed means first revenue may not begin at clearance at all but after a serial payer-policy campaign that carries its own cost and calendar and is currently costed at zero. Pediatric enrollment requiring an overnight in-lab reference study is also slow to recruit. This is a hero-bet capital profile attached to a niche indication | Trial-detail lookups on the two NCTs for realized enrollment, sites, and timelines (free, the best available benchmark); FDA MDUFA performance reports and the FDA De Novo decision-time listing (free); and a human-attached CRO quote for a…the rest of this gap analysismulti-site pediatric study (the quote itself is typically free) |
| Competitive intensity | 2 | Rests on claim 13unconfirmed (ResMed, ZOLL/Itamar and Philips hold cleared adult HSAT platforms one validation study away from this indication; the real question is whether the segment is large enough for them to bother). Scored 2 on the convention…the rest of this reasoningthat higher intensity is worse: the incumbents are well-capitalized, already cleared, already in the referral channel, and face a strictly lower barrier to this indication than a new entrant does, since they need only add a population to an existing platform. The apparent counterweight — that per claim 3refuted none of them has bothered — cuts both ways and neither way is good: either the segment is unattractive (a TAM problem) or the pediatric validation study is harder than claim 12unconfirmed prices it (a Factor 7 problem). The second half of claim 13unconfirmed is a guess about incumbent internal priorities with no source and no connector | A clearance-history pull over the trailing 5 years (free) settles the incumbent roster and cleared indications; a recall-history pull (free) adds safety-signal context; and a trial-detail lookup on the two NCTs' sponsor fields (free,…the rest of this gap analysisnear-decisive). Funding and launch activity needs a licensed source like PitchBook or Crunchbase (subscription cost) |
| Strategic fit & portfolio balance | 3 | No claim in this file speaks to strategic fit, and the repo contains no portfolio thesis, no stated capital constraints and no hero-bet-versus-cash-spoke allocation policy; calibration-log.md is still empty, so there is no track record…the rest of this reasoningto position against either. The 3 is a placeholder, not an assessment. What the file's own evidence does support as a characterization: this is a hero-bet profile — multi-year validation study, mid-single-digit-millions before revenue (claim 12unconfirmed), an unresolved regulatory fork, and a serial payer campaign after clearance (claim 9unconfirmed) — attached to a niche pediatric indication. That is a real description and still says nothing about whether it fits this portfolio, because no portfolio has been defined. At 5% weight this moves any future composite by at most 1 point either way. Read it as a null; it does not carry into Stage 4 | A human-authored portfolio thesis document covering current holdings, capital constraints, and hero-bet-vs-cash-spoke targets — no external source exists; the cost is internal strategy time, not a data fee |
All eight wrap criteria are met.
Source file: knowledge-base/candidates/idea-005.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md